Stoke Therapeutics Inc. surges following 'impressive' study data By Investing.com

Published on 26 Mar 2024 on Investing.com

Stoke Therapeutics Inc. surges following 'impressive' study data

Read the rest of the article

Start tracking your investments with Statfolio

For Immediate Release Chicago, IL – December 26, 2024 – Zacks.com announces the list of stocks...

Zacks · via Yahoo Finance 27 Dec 2024

We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are...

Insider Monkey · via Yahoo Finance 9 Oct 2024

On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:ST...

GuruFocus.com via Yahoo Finance 23 May 2024

Revenue: Reported $4.2 million for Q1 2024, up from $5.2 million in Q1 2023, exceeding the estima...

GuruFocus.com via Yahoo Finance 8 May 2024

With shares of Stoke Therapeutics Inc. trading at its highest level since October 2022, the biote...

The Business Journals 27 Mar 2024

Stoke Therapeutics, Inc. STOK reported encouraging new data from two phase I/IIa studies and two ...

Zacks via Yahoo Finance 27 Mar 2024

TD Cowen upgraded Stoke Therapeutics (STOK) to buy based on updated Phase 1/2 data for the compan...

Seeking Alpha 26 Mar 2024

Monday, Stoke Therapeutics Inc (NASDAQ:STOK) released new data from two open-label Phase 1/2a stu...

Benzinga via Yahoo Finance 26 Mar 2024

Stoke Therapeutics Inc STOK shares are rising in Tuesday’s after-hours session, riding a wave a m...

Benzinga 26 Mar 2024

Stoke Therapeutics Inc. surges following 'impressive' study data

Investing.com 26 Mar 2024